CAS
VNDA icon

CTC Alternative Strategies’s Vanda Pharmaceuticals VNDA Stock Holding History

CTC Alternative Strategies’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,400
Closed -$79.5K – 129
2023
Q3 		$79.5K Buy
+18,400
New +$102K 0.15% 64

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

CTC Alternative Strategies's VNDA Position: Q4 2023 in Review

CTC Alternative Strategies sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 18,400 shares — an estimated $79.5K sold.

CTC Alternative Strategies first reported a position in VNDA in Q3 2023 and held it in 1 quarter. The position peaked at $79.5K in Q3 2023. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

  • CTC Alternative Strategies reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • CTC Alternative Strategies sold 18,400 Vanda Pharmaceuticals shares in Q4 2023, an estimated $79.5K.
  • CTC Alternative Strategies first reported a position in Vanda Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • CTC Alternative Strategies's Vanda Pharmaceuticals position peaked at $79.5K in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on CTC Alternative Strategies's 13F filing for Q4 2023, filed 30 Jan 2024.